Sun Pharma shares fall 2.61%; stock among top losers on Nifty 50

Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Shares of Sun Pharma declined 2.61% to Rs 1,613.40 in Tuesday's session, making it one of the top losers on the Nifty 50. Other top losers on Nifty 50 included Shriram Finance, Tata Steel, Dr Reddys Labs and Coal India.

Quarterly Financial Performance:

The consolidated quarterly revenue for Sun Pharma has shown an increasing trend. For the quarter ending June 2024, the revenue was Rs 12,652.75 Crore, which increased to Rs 13,291.39 Crore for September 2024, Rs 13,675.46 Crore for December 2024, and Rs 12,958.84 Crore for March 2025. The latest quarter ending June 2025, shows a revenue of Rs 13,851.40 Crore.

Net profit also reflects fluctuations across the quarters. The net profit stood at Rs 2,871.25 Crore for June 2024, increased to Rs 3,030.67 Crore in September 2024, then slightly decreased to Rs 2,917.54 Crore in December 2024, and dropped to Rs 2,160.64 Crore in March 2025. However, it recovered to Rs 2,302.62 Crore for the quarter ending June 2025.

The EPS (Earnings Per Share) values align with the net profit trend, with values of Rs 11.80, Rs 12.70, Rs 12.10, Rs 9.00, and Rs 9.50 for the quarters from June 2024 to June 2025, respectively.

The consolidated annual revenue for Sun Pharma has consistently increased over the years. In 2021, the revenue was Rs 33,498.14 Crore, which grew to Rs 38,654.49 Crore in 2022, Rs 43,885.68 Crore in 2023, Rs 48,496.85 Crore in 2024, and reached Rs 52,578.44 Crore in 2025.

The net profit also shows a strong growth trend. Starting from Rs 2,284.68 Crore in 2021, it increased to Rs 3,405.82 Crore in 2022, surged to Rs 8,560.84 Crore in 2023, further rose to Rs 9,648.44 Crore in 2024, and reached Rs 10,980.10 Crore in 2025.

The EPS (Earnings Per Share) reflects this growth, with values of Rs 12.10, Rs 13.60, Rs 35.30, Rs 39.90, and Rs 45.60 for the years 2021 through 2025, respectively.

The BVPS (Book Value Per Share) has also increased steadily, from Rs 206.23 in 2021 to Rs 301.00 in 2025.

The ROE (Return on Equity) remained relatively stable, fluctuating between 6.24% in 2021 and 15.13% in 2025.

The debt-to-equity ratio has remained low, indicating a conservative capital structure, with values ranging from 0.07 in 2021 to 0.03 in 2025.

The sales for Sun Pharma have shown consistent growth over the past five years. Sales increased from Rs 33,498 Crore in March 2021 to Rs 52,578 Crore in March 2025.

Other income has fluctuated, with a high of Rs 1,965 Crore in March 2025 and a low of Rs 634 Crore in March 2023.

Total income increased from Rs 34,333 Crore in March 2021 to Rs 54,543 Crore in March 2025.

Total expenditure also increased, from Rs 31,392 Crore in March 2021 to Rs 40,559 Crore in March 2025.

Earnings Before Interest and Taxes (EBIT) increased from Rs 2,940 Crore in March 2021 to Rs 13,983 Crore in March 2025.

Interest expenses have remained relatively stable, ranging from Rs 127 Crore in March 2022 to Rs 238 Crore in March 2024.

Tax expenses have varied, from Rs 514 Crore in March 2021 to Rs 2,772 Crore in March 2025.

Net profit has shown substantial growth, from Rs 2,284 Crore in March 2021 to Rs 10,980 Crore in March 2025.

Cash flow from operating activities has been consistently positive, with the highest value of Rs 14,072 Crore in March 2025 and the lowest of Rs 4,959 Crore in March 2023.

Investing activities showed negative cash flow in most years, indicating investments in assets. The most significant outflow was Rs 7,943 Crore in March 2023.

Financing activities also generally showed negative cash flow, reflecting the company's focus on managing its capital structure and returning value to shareholders. The largest outflow was Rs 6,710 Crore in March 2024.

Net cash flow has varied, with a high of Rs 4,661 Crore in March 2024 and a low of -Rs 1,764 Crore in March 2022.

Share capital has remained constant at Rs 239 Crore from 2021 to 2025.

Reserves & surplus have increased steadily from Rs 46,222 Crore in 2021 to Rs 71,978 Crore in 2025.

Current liabilities have fluctuated, with the highest value of Rs 19,907 Crore in 2023 and the lowest of Rs 16,145 Crore in 2021.

Other liabilities have remained relatively stable, ranging from Rs 4,588 Crore in 2022 to Rs 5,058 Crore in 2021.

Total liabilities have increased from Rs 67,666 Crore in 2021 to Rs 92,100 Crore in 2025.

Fixed assets have shown a gradual increase, from Rs 16,832 Crore in 2021 to Rs 20,290 Crore in 2025.

Current assets have increased from Rs 30,442 Crore in 2021 to Rs 52,624 Crore in 2025.

Other assets have fluctuated, with the highest value of Rs 22,021 Crore in 2024 and the lowest of Rs 17,587 Crore in 2022.

Total assets have increased from Rs 67,666 Crore in 2021 to Rs 92,100 Crore in 2025, matching the increase in total liabilities.

Basic and Diluted EPS both stand at Rs 45.60 for March 2025, compared to Rs 39.90 in March 2024.

Book Value per Share has increased from Rs 206.23 in March 2021 to Rs 301.00 in March 2025.

Dividend per Share has increased steadily, reaching Rs 16.00 in March 2025.

The Debt to Equity ratio is low at 0.03x in March 2025.

Interest Coverage Ratio is strong at 74.50x in March 2025.

Sun Pharma has announced several corporate actions, including analyst/investor meetings and earnings call transcripts. The company announced a final dividend of Rs 5.50 per share (550%) on May 22, 2025, with an effective date of July 7, 2025. Additionally, an interim dividend of Rs 10.50 per share (1050%) was announced on January 16, 2025, with an effective date of February 6, 2025.

The stock is currently facing bearish sentiment, according to a Moneycontrol analysis dated August 21, 2025.